Top-News

Zymeworks Aktie News

Aktie
WKN:  A3DSSN ISIN:  US98985Y1082 US-Symbol:  ZYME Branche:  Biotechnologie Land:  USA
26,69 $
+0,17 $
+0,64%
22,922 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
1,10 Mrd. €
Streubesitz
-
KGV
-9,04
Index-Zuordnung
-

Zymeworks News

25.03.25 - GlobeNewswire
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile
26.02.25 - GlobeNewswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-​stage biotechnology company developing a diverse pipeline of ...
25.02.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
13.02.25 - GlobeNewswire
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
30.01.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
08.01.25 - GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Investigational new drug (IND) applications for initiating first-​in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applications for initiating first-​in-human ...
12.12.24 - GlobeNewswire
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a novel ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »